pembrolizumab


( Last Updated : May 6, 2021)
Generic Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Classical Hodgkin lymphoma
Manufacturer:
Merck Canada
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0236-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 10, 2020
Call for patient/clinician input closedFebruary 05, 2021
Clarification:

- Patient input submission received from Lymphoma Canada

Submission receivedJanuary 29, 2021
Submission accepted
Review initiatedMarch 11, 2021
Draft CADTH review report(s) provided to sponsor for commentMay 28, 2021
Deadline for sponsors commentsJune 08, 2021
CADTH responses on draft review report(s) provided to sponsorJuly 05, 2021
Expert committee meeting (initial)July 15, 2021
Draft recommendation issued to sponsorJuly 27, 2021
To
July 29, 2021
Draft recommendation posted for stakeholder feedback